xpovio
xpovio: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | Approved |
FDA Decisions
Frequently asked questions
Who is developing xpovio?
xpovio is being developed by Karyopharm Therapeutics Inc..
What is xpovio's latest FDA decision?
The most recent tracked FDA decision for xpovio is Approval for 1 INDICATIONS AND USAGE XPOVIO is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ( 1.1 ). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory age, dated July 3, 2019.
Get deeper analysis on xpovio
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis